| Lymphoma, Follicular
Lunsumio vs Gazyva
Side-by-side clinical, coverage, and cost comparison for lymphoma, follicular.Deep comparison between: Lunsumio vs Gazyva with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsGazyva has a higher rate of injection site reactions vs Lunsumio based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Gazyva but not Lunsumio, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Lunsumio
Gazyva
At A Glance
IV infusion
Every 3 weeks
Bispecific CD20xCD3 T-cell engager
IV infusion
Anti-CD20 monoclonal antibody
Indications
- Lymphoma, Follicular
- Chronic Lymphocytic Leukemia
- Lymphoma, Follicular
- Lupus Nephritis
Dosing
Lymphoma, Follicular Step-up dosing: 1 mg IV (Cycle 1 Day 1), 2 mg (Cycle 1 Day 8), 60 mg (Cycle 1 Day 15), 60 mg (Cycle 2 Day 1), then 30 mg every 3 weeks (Cycles 3+); 21-day cycles; administer as IV infusion over a minimum of 4 hours for initial doses.
Chronic Lymphocytic Leukemia 100 mg IV on day 1 and 900 mg on day 2 of Cycle 1, then 1,000 mg on days 8 and 15 of Cycle 1, and 1,000 mg on day 1 of Cycles 2-6 (28-day cycles) in combination with chlorambucil.
Lymphoma, Follicular 1,000 mg IV on days 1, 8, and 15 of Cycle 1, then 1,000 mg on day 1 of Cycles 2-6 or 2-8 in combination with chemotherapy; responding patients continue on 1,000 mg monotherapy every 2 months for up to 2 years.
Lupus Nephritis 1,000 mg IV at initial infusion (Dose 1), at Week 2 (Dose 2), at Week 24 (Dose 3), at Week 26 (Dose 4), then 1,000 mg every 6 months thereafter, in combination with standard therapy.
Contraindications
—
- Known hypersensitivity reaction (e.g., anaphylaxis) to obinutuzumab or any excipient
- Serum sickness with prior obinutuzumab use
Adverse Reactions
Most common (>=10%) CRS, fatigue, rash, pyrexia, headache, musculoskeletal pain, cough, pruritus, peripheral neuropathy, edema, diarrhea, nausea, dry skin, upper respiratory tract infection, chills, dizziness, insomnia, abdominal pain, arthralgia, dyspnea, skin exfoliation, urinary tract infection
Serious CRS, infections (sepsis, pneumonia, urinary tract infection, EBV viremia, COVID-19, upper respiratory tract infection), renal insufficiency, pyrexia, tumor flare
Most common (>=10%) Infusion-related reactions, neutropenia, thrombocytopenia, diarrhea, fatigue, upper respiratory tract infection, musculoskeletal pain
Serious Hepatitis B virus reactivation, progressive multifocal leukoencephalopathy, infusion-related reactions, hypersensitivity reactions including serum sickness, tumor lysis syndrome, infections, neutropenia, thrombocytopenia, disseminated intravascular coagulation
Postmarketing Serum sickness
Pharmacology
Mosunetuzumab-axgb is a bispecific CD20-directed CD3 T-cell engaging antibody that binds CD3 on T-cells and CD20 on lymphoma and B-lineage cells, activating T-cells to induce B-cell lysis and cytokine release.
Obinutuzumab is a humanized anti-CD20 IgG1 monoclonal antibody with reduced fucose content that mediates B-cell lysis via immune effector cell engagement (ADCC and ADCP), direct intracellular death signaling, and complement activation; its reduced fucose content confers greater ADCC activity than rituximab.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Lunsumio
- Covered on 5 commercial plans
- PA (9/12) · Step Therapy (0/12) · Qty limit (0/12)
Gazyva
- Covered on 5 commercial plans
- PA (11/12) · Step Therapy (0/12) · Qty limit (0/12)
UnitedHealthcare
Lunsumio
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Gazyva
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Humana
Lunsumio
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (0/3)
Gazyva
- Covered on 0 commercial plans
- PA (2/3) · Step Therapy (0/3) · Qty limit (2/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
Cost estimate not availableCancerCare: Non-Hodgkin Lymphoma
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Cost estimate not availableAssistance Fund: Chronic Lymphocytic Leukemia (CLL)
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
LunsumioView full Lunsumio profile
GazyvaView full Gazyva profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.